INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

Stock Information for INVO BioScience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About INVO BioScience Inc.

INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA
INVO Reports Record First Quarter 2024 Financial Results
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK(TM) Bispecific Antibody in the American Society of Hematology's Blood Journal
NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK(TM) Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.